Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: VEGFR1 and VEGFR2
Sponsor: Tokyo University
Collaborators: Human Genome Center, Institute of Medical Science, University of Tokyo